Pharmacological therapy for cystic fibrosis: From bench to bedside

Frédéric Becq, Marcus A. Mall, David N. Sheppard, Massimo Conese, Olga Zegarra-Moran

Research output: Contribution to journalArticlepeer-review

Abstract

With knowledge of the molecular behaviour of the cystic fibrosis transmembrane conductance regulator (CFTR), its physiological role and dysfunction in cystic fibrosis (CF), therapeutic strategies are now being developed that target the root cause of CF rather than disease symptoms. Here, we review progress towards the development of rational new therapies for CF. We highlight the discovery of small molecules that rescue the cell surface expression and defective channel gating of CF mutants, termed CFTR correctors and CFTR potentiators, respectively. We draw attention to alternative approaches to restore epithelial ion transport to CF epithelia, including inhibitors of the epithelial Na+ channel (ENaC) and activators of the Ca2+-activated Cl- channel TMEM16A. The expertise required to translate small molecules identified in the laboratory to drugs for CF patients depends on our ability to coordinate drug development at an international level and our ability to provide pertinent biological information using suitable disease models.

Original languageEnglish
JournalJournal of Cystic Fibrosis
Volume10
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Jul 2011

Keywords

  • Airway surface fluid
  • CFTR
  • CFTR correctors
  • CFTR potentiators
  • ENaC
  • F508del

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Pharmacological therapy for cystic fibrosis: From bench to bedside'. Together they form a unique fingerprint.

Cite this